NCT05462743

Brief Summary

Currently, the Correa cascade is a widely accepted model of gastric carcinogenesis. Intestinal metaplasia is a high risk factor for gastric cancer. According to Sydney criteria, mild intestinal metaplasia was not associated with gastric cancer, while moderate to severe intestinal metaplasia was strongly associated with the development of gastric cancer. Because intestinal metaplasia is distributed in various forms, the use of white light endoscopy lacks specificity, and the consistency with histopathological diagnosis is poor; Pathological biopsy is still needed to make a diagnosis. At present, national guidelines suggest that OLGIM score should be used to evaluate the risk of gastric cancer, and patients with OLGIM grade III/IV should be monitored by close gastroscopy. However, it requires at least four biopsies, which is clinically infeasible. Confocal laser endomicroscopy allows real-time observation of living tissue, comparable to pathological findings.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2022

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

July 9, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 18, 2022

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2023

Completed
Last Updated

July 18, 2022

Status Verified

July 1, 2022

Enrollment Period

1.5 years

First QC Date

July 9, 2022

Last Update Submit

July 13, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • Accuracy of AI model in assessing degree of intestinal metaplasia

    Pathological biopsy results were used as the gold standard to assess the accuracy of the AI model in diagnosing the degree of intestinal metaplasia at the biopsy site

    2 years

  • Sensitivity of AI model to assess degree of intestinal metaplasia

    The sensitivity of the AI model to diagnose the degree of intestinal metaplasia at the biopsy site was assessed using pathological biopsy results as the gold standard

    2 years

  • Specificity of AI model to assess degree of intestinal metaplasia

    Pathological biopsy results were used as the gold standard to assess the specificity of the AI model in diagnosing the degree of intestinal metaplasia at the biopsy site

    2 years

Study Arms (2)

group for training the algorithm

This group of images is used for training the algorithm of the artifical intelligence

group for testing the algorithm

This group of images is used for testing the algorithm of the artifical intelligence

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Consecutive patients who receive the upper gastrointestinal tract pCLE examination and screened that fulfill the eligibility criteria at Qilu Hospital, Shandong University will be enrolled into the study.

You may qualify if:

  • Patients aged 18-80 years undergoing confocal gastroscopy

You may not qualify if:

  • Patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in gastroscopy
  • Patients with previous surgical procedures on the stomach
  • Patients with contraindications to biopsy
  • Patients who refuse to sign the informed consent form

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Qilu Hospital, Shandong University

Jinan, Shandong, 250001, China

RECRUITING

Biospecimen

Retention: NONE RETAINED

When a gastric mucosal leison is found using white light endoscopy, endoscopist will observe this lesion using pCLE and then take biopsy for histology examination.

Study Officials

  • Yanqing Li

    Qilu Hospital of Shandong University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Vice President of Qilu Hospital

Study Record Dates

First Submitted

July 9, 2022

First Posted

July 18, 2022

Study Start

July 1, 2022

Primary Completion

December 30, 2023

Study Completion

December 30, 2023

Last Updated

July 18, 2022

Record last verified: 2022-07

Locations